A benefit for renal function after early switch to liposomal amphotericin B from conventional formulation in empirical antifungal treatment.
Isnard
Françoise
F
Tilleul
Patrick
P
Laporte
Jean-Philippe
JP
Chevallier
Patrice
P
Pigneux
Arnaud
A
Lafuma
Antoine
A
Mahi
Lamine
L
Deray
Gilbert
G
D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004337:Drug Carriers; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000382:microbiology*; D007674:Kidney Diseases / Q000209:etiology / Q000382:microbiology*; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy / Q000517:prevention & control; D009503:Neutropenia / Q000188:drug therapy*
D000935:Antifungal Agents; D004337:Drug Carriers; D000666:Amphotericin B